MA54648A - Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales - Google Patents
Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumoralesInfo
- Publication number
- MA54648A MA54648A MA054648A MA54648A MA54648A MA 54648 A MA54648 A MA 54648A MA 054648 A MA054648 A MA 054648A MA 54648 A MA54648 A MA 54648A MA 54648 A MA54648 A MA 54648A
- Authority
- MA
- Morocco
- Prior art keywords
- tumor cells
- wnt signaling
- biparatopic polypeptides
- antagonists
- polypeptides antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15197999 | 2015-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54648A true MA54648A (fr) | 2021-11-10 |
Family
ID=54782606
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054648A MA54648A (fr) | 2015-12-04 | 2016-12-02 | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
MA43368A MA43368B1 (fr) | 2015-12-04 | 2016-12-02 | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43368A MA43368B1 (fr) | 2015-12-04 | 2016-12-02 | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales |
Country Status (34)
Country | Link |
---|---|
US (2) | US10597449B2 (fr) |
EP (2) | EP3383425B1 (fr) |
JP (2) | JP6728355B2 (fr) |
KR (1) | KR20180081825A (fr) |
CN (1) | CN108289943B (fr) |
AR (1) | AR106949A1 (fr) |
AU (1) | AU2016363787B2 (fr) |
BR (1) | BR112018010537A2 (fr) |
CA (1) | CA3006235A1 (fr) |
CL (1) | CL2018001384A1 (fr) |
CO (1) | CO2018005680A2 (fr) |
CY (1) | CY1123454T1 (fr) |
DK (1) | DK3383425T3 (fr) |
EA (1) | EA201891331A1 (fr) |
ES (1) | ES2821099T3 (fr) |
HK (1) | HK1255725A1 (fr) |
HR (1) | HRP20201528T1 (fr) |
HU (1) | HUE051777T2 (fr) |
IL (1) | IL259119B (fr) |
LT (1) | LT3383425T (fr) |
MA (2) | MA54648A (fr) |
MX (1) | MX2018006760A (fr) |
MY (1) | MY200933A (fr) |
PE (1) | PE20181515A1 (fr) |
PH (1) | PH12018501155A1 (fr) |
PL (1) | PL3383425T3 (fr) |
PT (1) | PT3383425T (fr) |
RS (1) | RS60823B1 (fr) |
SA (1) | SA518391728B1 (fr) |
SG (1) | SG11201804510PA (fr) |
SI (1) | SI3383425T1 (fr) |
TW (1) | TWI734719B (fr) |
UA (1) | UA122079C2 (fr) |
WO (1) | WO2017093478A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013130364A1 (fr) | 2012-02-28 | 2013-09-06 | Novartis Ag | Sélection de patient atteints d'un cancer pour administrer des inhibiteurs de signalisation de la voie wnt au moyen de l'état de mutation rnf43 |
EA201891165A1 (ru) | 2015-11-18 | 2018-11-30 | Мерк Шарп И Доум Корп. | Молекулы, связывающие pd1 и/или lag3 |
KR20180081825A (ko) * | 2015-12-04 | 2018-07-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
UA125761C2 (uk) * | 2017-05-31 | 2022-06-01 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Поліпептид, який перешкоджає передачі wnt-сигналів у пухлинних клітинах |
AU2018316166A1 (en) | 2017-08-07 | 2020-02-06 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
KR20200106495A (ko) * | 2017-11-29 | 2020-09-14 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료요법을 위한 조성물 및 방법 |
WO2020080941A1 (fr) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anticorps anti-protéine 5/6 associée au récepteur de lipoprotéines de faible densité |
CA3130663A1 (fr) | 2019-03-29 | 2020-10-08 | Boehringer Ingelheim International Gmbh | Polytherapie anticancereuse |
JP2022526166A (ja) | 2019-03-29 | 2022-05-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗癌併用療法 |
WO2020227071A1 (fr) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Polypeptides se liant à cd123 et leurs utilisations |
JP2022531718A (ja) * | 2019-05-08 | 2022-07-08 | 2セブンティ バイオ インコーポレイテッド | Cd123標的免疫療法 |
AU2020329092A1 (en) * | 2019-08-14 | 2022-03-31 | Antlera Therapeutics Inc. | Antibodies that bind to LRP5 proteins and methods of use |
JP2022544307A (ja) * | 2019-08-14 | 2022-10-17 | モッドマブ セラピューティクス インコーポレイテッド | Lrp6タンパク質に結合する抗体および使用方法 |
CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
WO2021163490A1 (fr) * | 2020-02-14 | 2021-08-19 | University Of Washington | Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable |
US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
EP4372006A1 (fr) * | 2021-07-16 | 2024-05-22 | Brightpath Biotherapeutics Co., Ltd. | Anticorps ou dérivé d'anticorps anti-antigène tim-3, et utilisation associée |
CN116375851B (zh) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1621554B2 (fr) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulines dépourvus de chaînes légères |
EP0739981A1 (fr) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
EP1278544A4 (fr) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Proteines hybrides d'albumine |
WO2003002609A2 (fr) | 2001-06-28 | 2003-01-09 | Domantis Limited | Ligand |
EP1463752A4 (fr) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Proteines de fusion d'albumine |
EP1558645B1 (fr) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation |
EP1814917A2 (fr) | 2004-10-13 | 2007-08-08 | Ablynx N.V. | Anticorps anti bêta-amyloïdes à domaine camélide unique et les polypeptides les comprenant pour le traitment et le diagnostic de maladies neuronales dégénératives telles que la maladie d'alzheimer |
ATE537188T1 (de) | 2005-05-18 | 2011-12-15 | Ablynx Nv | Serumalbuminbindende proteine |
WO2007142987A2 (fr) * | 2006-05-30 | 2007-12-13 | Wisconsin Alumni Research Foundation | Marqueur de cellules souches mammaires |
EP2447558B1 (fr) | 2006-06-08 | 2013-05-29 | NSK Ltd. | Procédé de fabrication d'un roulement à billes à douille doté d'une bague d'étanchéité |
JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
CN100428934C (zh) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
AU2008320823B2 (en) | 2007-11-02 | 2013-01-17 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
WO2009127691A1 (fr) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capables de se lier à des protéines sériques et composés, constructions et polypeptides les comprenant |
US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
BR112012017051A2 (pt) | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | método para diminuir a imunogenicidade |
CA2788993A1 (fr) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capables de se lier a la serumalbumine, et composes, constructions, et polypeptides comprenant de tels peptides |
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
KR101899835B1 (ko) * | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | 항-lrp6 항체 |
CN103237811A (zh) * | 2010-05-06 | 2013-08-07 | 诺瓦提斯公司 | 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法 |
CA2798432A1 (fr) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions et procedes d'utilisation d'anticorps therapeutiques diriges contre la proteine 6 liee a la lipoproteine de basse densite (lrp6) |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
MX350074B (es) | 2011-06-23 | 2017-08-25 | Ablynx Nv | Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. |
MX2014001883A (es) | 2011-08-17 | 2014-05-27 | Glaxo Group Ltd | Proteinas y peptidos modificados. |
MX2014005411A (es) | 2011-11-04 | 2015-02-12 | Novartis Ag | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
JP5949270B2 (ja) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム |
EP2888279A1 (fr) * | 2012-08-22 | 2015-07-01 | Glaxo Group Limited | Anticorps anti-lrp6 |
KR20180081825A (ko) | 2015-12-04 | 2018-07-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드 |
-
2016
- 2016-12-02 KR KR1020187019053A patent/KR20180081825A/ko not_active Application Discontinuation
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/ja active Active
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/da active
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 PL PL16808971T patent/PL3383425T3/pl unknown
- 2016-12-02 MX MX2018006760A patent/MX2018006760A/es unknown
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/fr active Application Filing
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/fr active Active
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/hu unknown
- 2016-12-02 SI SI201630953T patent/SI3383425T1/sl unknown
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/zh active Active
- 2016-12-02 CA CA3006235A patent/CA3006235A1/fr active Pending
- 2016-12-02 ES ES16808971T patent/ES2821099T3/es active Active
- 2016-12-02 TW TW105139826A patent/TWI734719B/zh active
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/lt unknown
- 2016-12-02 EA EA201891331A patent/EA201891331A1/ru unknown
- 2016-12-02 AR ARP160103720A patent/AR106949A1/es unknown
- 2016-12-02 MA MA054648A patent/MA54648A/fr unknown
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/pt active Search and Examination
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 PT PT168089712T patent/PT3383425T/pt unknown
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/es unknown
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/fr not_active Withdrawn
- 2016-12-02 RS RS20201124A patent/RS60823B1/sr unknown
- 2016-12-02 UA UAA201807120A patent/UA122079C2/uk unknown
- 2016-12-02 MA MA43368A patent/MA43368B1/fr unknown
-
2018
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/es unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/es unknown
- 2018-06-01 PH PH12018501155A patent/PH12018501155A1/en unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/ar unknown
- 2018-11-21 HK HK18114876.0A patent/HK1255725A1/zh unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/ja not_active Withdrawn
- 2020-09-24 HR HRP20201528TT patent/HRP20201528T1/hr unknown
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54648A (fr) | Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales | |
IL266145B (en) | Methods for using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors | |
MA47580A (fr) | Cellules immunitaires bipartites et tripartites de signalisation | |
DK3560953T5 (da) | Celle | |
MA48760A (fr) | Polypeptides ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales | |
FR3021533B1 (fr) | Composition cosmetique de type gel | |
DK3254325T3 (da) | Elektrolytdannelsesfremgangsmåde | |
DK3228731T3 (da) | Oxygen-genererende anode | |
DK3254326T3 (da) | Elektrolytdannelsesfremgangsmåde | |
ES2808978T8 (es) | Heteroarilamidas como inhibidores de la agregación de proteínas | |
DK3209323T3 (da) | Forbedret koaguleringssammensætning | |
DK3169232T3 (da) | Intermitterende måling af partialtrykket af en analyt i hudvæv | |
DK3188721T3 (da) | Humane terapeutika | |
BR112017000271A2 (pt) | chip de sensor eletroquímico | |
CL2015000372S1 (es) | Telefono celular | |
ES2739642T8 (es) | Balasto y procedimiento de obtención del mismo | |
FR3025098B1 (fr) | Composition cosmetique de type gel facilement demaquillable | |
DK3234597T3 (da) | Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme | |
HK1213274A1 (zh) | 變體因子 多肽及其產生和使用方法 | |
BR112017003965A2 (pt) | polipeptídeos vip3 modificados | |
FI20145079A (fi) | Järjestely vesiaktiviteetteja varten | |
FR3024451B1 (fr) | Nouveaux sels de strombine et leur utilisation cosmetique | |
TH1501006107B (th) | เซลล์อิเล็กโทรไลต์สำหรับการสกัดโลหะด้วยไฟฟ้า | |
ITUB20152344A1 (it) | Purificatore d’acqua curativo | |
TH1601001571B (th) | องค์ประกอบของสารเจือสีและวิธีการผลิตนั้น |